74632-30-7Relevant academic research and scientific papers
Pyrido/pyridazocyclic compound and application thereof
-
Paragraph 0208-0212, (2019/12/25)
The invention discloses a pyrido/pyridazocyclic compound, a pharmaceutically acceptable salt and a solvent compound thereof. The invention further provides a preparation method of the compound, a composition with the compound and application of the compound for preparing medicines for treating diseases or disorders related to EED (embryonic ectoderm development) protein and/or PRC2 (polycomb repressive complex 2) protein composition action mechanisms.
BROMODOMAIN INHIBITORS
-
Paragraph 0978; 0979, (2015/04/28)
The present invention relates to substituted heterocyclic derivative compounds, compositions comprising said compounds, and the use of said compounds and compositions for epigenetic regulation by inhibition of bromodomain-mediated recognition of acetyl lysine regions of proteins, such as histones. Said compositions and methods are useful for the treatment of cancer and neoplastic disease.
Evaluation of 2-thioxo-2,3,5,6,7,8-hexahydropyrimido[4,5-d]pyrimidin-4(1H)-one analogues as GAA activators
Marugan, Juan J.,Zheng, Wei,Motabar, Omid,Southall, Noel,Goldin, Ehud,Sidransky, Ellen,Aungst, Ronald A.,Liu, Ke,Sadhukhan, Subir Kumar,Austin, Christopher P.
experimental part, p. 1880 - 1897 (2010/07/04)
Pompe disease is a lysosomal storage disease (LSD) caused by a deficiency in the lysosomal enzyme acid alpha-glucosidase. In several LSDs, enzyme inhibitors have been used as small molecule chaperones to facilitate and increase the translocation of mutant protein from the endoplasmic reticulum to the lysosome. Enzyme activators with chaperone activity would be even more desirable as they would not inhibit the enzyme after translocation and might potentiate the activity of the enzyme that is successfully translocated. Herein we report our initial findings of a new series of acid alpha-glucosidase activators.
